Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Intellia Therapeutics ( (NTLA) ) has shared an update.
On October 29, 2025, Intellia Therapeutics was informed by the FDA of a clinical hold on their Phase 3 trials for nexiguran ziclumeran due to safety concerns. The hold follows reports of severe liver issues in a patient, prompting the company to pause the trials and work with the FDA to resolve the matter.
The most recent analyst rating on (NTLA) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
Intellia Therapeutics’ overall stock score reflects a challenging financial environment typical for a biotech in development, with high R&D expenses and negative cash flows. However, the company shows strong technical indicators and promising clinical trial progress, which are positive signs for future growth. The earnings call provided reassurance with a solid cash runway and positive trial data, although valuation remains a concern due to ongoing losses.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
Average Trading Volume: 6,600,610
Technical Sentiment Signal: Sell
Current Market Cap: $1.5B
Learn more about NTLA stock on TipRanks’ Stock Analysis page.